Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      1Department of Psychiatry, Yale University School of Medicine, CMHC, SAC 202
      2Yale School of Public Health
    • Publication Date:
      2009
    • Author Keywords:
      Drinking reduction
      Heavy drinking
      Measurement sensitivity
      Naltrexone
      Smoking cessation
    • ISSN:
      14611457
      14695111
    • Accession Number:
      10.1017/S146114570800936X
    • Rights:
      Copyright 2010 Elsevier B.V., All rights reserved.
    • Accession Number:
      edselc.2-52.0-69749096667
  • Citations
    • ABNT:
      O’MALLEY, S. S. ( 1 ) et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology, [s. l.], v. 12, n. 5, p. 589–597, [s. d.]. DOI 10.1017/S146114570800936X. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselc&AN=edselc.2-52.0-69749096667. Acesso em: 24 out. 2020.
    • AMA:
      O’Malley SS( 1 ), Krishnan-Sarin S( 1 ), McKee SA( 1 ), et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology. 12(5):589-597. doi:10.1017/S146114570800936X
    • APA:
      O’Malley, S. S. ( 1 ), Krishnan-Sarin, S. ( 1 ), McKee, S. A. ( 1 ), Leeman, R. F. ( 1 ), Cooney, N. L. ( 1 ), Meandzija, B. ( 1 ), Wu, R. ( 1 ), & Makuch, R. W. ( 2 ). (n.d.). Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology, 12(5), 589–597. https://doi.org/10.1017/S146114570800936X
    • Chicago/Turabian: Author-Date:
      O’Malley, S.S. ( 1 ), S. ( 1 ) Krishnan-Sarin, S.A. ( 1 ) McKee, R.F. ( 1 ) Leeman, N.L. ( 1 ) Cooney, B. ( 1 ) Meandzija, R. ( 1 ) Wu, and R.W. ( 2 ) Makuch. 2020. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” International Journal of Neuropsychopharmacology 12 (5): 589–97. Accessed October 24. doi:10.1017/S146114570800936X.
    • Harvard:
      O’Malley, S. S. ( 1 ) et al. (no date) ‘Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation’, International Journal of Neuropsychopharmacology, 12(5), pp. 589–597. doi: 10.1017/S146114570800936X.
    • Harvard: Australian:
      O’Malley, SS( 1 ), Krishnan-Sarin, S( 1 ), McKee, SA( 1 ), Leeman, RF( 1 ), Cooney, NL( 1 ), Meandzija, B( 1 ), Wu, R( 1 ) & Makuch, RW( 2 ) n.d., ‘Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation’, International Journal of Neuropsychopharmacology, vol. 12, no. 5, pp. 589–597, viewed 24 October 2020, .
    • MLA:
      O’Malley, S. S. (. 1. )., et al. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” International Journal of Neuropsychopharmacology, vol. 12, no. 5, pp. 589–597. EBSCOhost, doi:10.1017/S146114570800936X. Accessed 24 Oct. 2020.
    • Chicago/Turabian: Humanities:
      O’Malley, S.S. ( 1 ), S. ( 1 ) Krishnan-Sarin, S.A. ( 1 ) McKee, R.F. ( 1 ) Leeman, N.L. ( 1 ) Cooney, B. ( 1 ) Meandzija, R. ( 1 ) Wu, and R.W. ( 2 ) Makuch. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” International Journal of Neuropsychopharmacology 12, no. 5: 589–97. Accessed October 24, 2020. doi:10.1017/S146114570800936X.
    • Vancouver/ICMJE:
      O’Malley SS( 1 ), Krishnan-Sarin S( 1 ), McKee SA( 1 ), Leeman RF( 1 ), Cooney NL( 1 ), Meandzija B( 1 ), et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology [Internet]. [cited 2020 Oct 24];12(5):589–97. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselc&AN=edselc.2-52.0-69749096667